Research advances on microRNA in amyotrophic lateral sclerosis

Read full text Summarise with VIRAT
Authors: Jialin YAO, Xiaoyan XU, Yunxiang Guan, Baicheng Qian, Baoliang WANG
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Amyotrophic lateral sclerosis (ALS) is a rare neurological disorder affecting both upper and lower motor neurons. Its pathogenesis remains unclear, and there is currently no effective treatment. A growing body of research indicates that patients with ALS exhibit alterations in the expression profiles of various microRNAs (miRNAs), which are involved in multiple key pathogenic mechanisms of the disease, including misfolded protein aggregation, apoptosis, and mitochondrial dysfunction. These miRNAs also hold potential as biomarkers for the diagnosis and prognosis assessment. Furthermore, therapeutic strategies targeting miRNAs—such as the delivery of miRNAs via exosomes, artificial miRNA technology, and miRNA inhibitors—have shown promise for treatment. This article reviews the research progress on miRNAs in ALS from the perspectives of pathogenesis, biomarkers, and therapy, aiming to provide new strategies for the diagnosis and treatment of ALS.

Fields of Study & Subjects

Amyotrophic Lateral Sclerosis Research MicroRNA in disease regulation Muscle Physiology and Disorders

Publication details

Journal / source
DOAJ (DOAJ: Directory of Open Access Journals)
Publication date
1 March 2026
Language
ZH